Metabolism
Serine/threonine kinase AMPK upregulates glucose uptake by promoting the expression and function of glucose transporters. AMPK is activated by increased AMP/ATP ratio, resulting from cellular and environmental stress, e.g. low glucose, heat shock, hypoxia and ischemia. AMPK activation positively modulates signaling transductions that refill ATP levels. Moreover, it also stimulates catabolic processes such as fatty acid oxidation and glycolysis through inhibition of ACC and activation of PFK2. AMPK negatively regulates various proteins which are important to ATP-consuming mechanisms, e.g. mTORC2, glycogen synthase, SREBP-1, and TSC2, causing the downregulation/inhibition of gluconeogenesis and glycogen, lipid and protein synthesis.
- A4365 LovastatinTarget: HMG-CoA ReductasesSummary: HMG-CoA reductase inhibitor
- A4373 NLG9191 CitationSummary: Potent IDO pathway inhibitor
- A4381 FK866 (APO866)1 CitationTarget: NamptSummary: NAMPT inhibitor, non-competitive, highly specific
- A4383 TolcaponeTarget: Catechol O-Methyltransferase (COMT)Summary: COMT inhibitor
- A4390 Pemetrexed1 CitationTarget: Thymidylate Synthase|DHFR|GARFTSummary: TS, DHFR,GARFT and AICARFT inhibitor
- A3358 DeltarasinTarget: Phosphodiesterases (PDEs)Summary: KRAS-PDEδ interaction inhibitor
- A3493 INCB024360 analogueSummary: potent and selective inhibitor of IDO1